JPWO2022249942A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022249942A5
JPWO2022249942A5 JP2023523431A JP2023523431A JPWO2022249942A5 JP WO2022249942 A5 JPWO2022249942 A5 JP WO2022249942A5 JP 2023523431 A JP2023523431 A JP 2023523431A JP 2023523431 A JP2023523431 A JP 2023523431A JP WO2022249942 A5 JPWO2022249942 A5 JP WO2022249942A5
Authority
JP
Japan
Prior art keywords
glaucoma
prophylactic
age
pharmaceutically acceptable
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023523431A
Other languages
English (en)
Japanese (ja)
Other versions
JP7427308B2 (ja
JPWO2022249942A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/020635 external-priority patent/WO2022249942A1/ja
Publication of JPWO2022249942A1 publication Critical patent/JPWO2022249942A1/ja
Publication of JPWO2022249942A5 publication Critical patent/JPWO2022249942A5/ja
Priority to JP2024004935A priority Critical patent/JP2024032794A/ja
Application granted granted Critical
Publication of JP7427308B2 publication Critical patent/JP7427308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023523431A 2021-05-24 2022-05-18 網膜の神経細胞の保護剤 Active JP7427308B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024004935A JP2024032794A (ja) 2021-05-24 2024-01-17 網膜の神経細胞の保護剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021086920 2021-05-24
JP2021086920 2021-05-24
JP2021172191 2021-10-21
JP2021172191 2021-10-21
PCT/JP2022/020635 WO2022249942A1 (ja) 2021-05-24 2022-05-18 網膜の神経細胞の保護剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024004935A Division JP2024032794A (ja) 2021-05-24 2024-01-17 網膜の神経細胞の保護剤

Publications (3)

Publication Number Publication Date
JPWO2022249942A1 JPWO2022249942A1 (https=) 2022-12-01
JPWO2022249942A5 true JPWO2022249942A5 (https=) 2023-12-11
JP7427308B2 JP7427308B2 (ja) 2024-02-05

Family

ID=84230063

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023523431A Active JP7427308B2 (ja) 2021-05-24 2022-05-18 網膜の神経細胞の保護剤
JP2024004935A Pending JP2024032794A (ja) 2021-05-24 2024-01-17 網膜の神経細胞の保護剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024004935A Pending JP2024032794A (ja) 2021-05-24 2024-01-17 網膜の神経細胞の保護剤

Country Status (3)

Country Link
JP (2) JP7427308B2 (https=)
TW (1) TWI901889B (https=)
WO (1) WO2022249942A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7652070B2 (en) * 2007-04-02 2010-01-26 Benjamin Rubin Treatment method for MMP-implicated pathologies
WO2015069888A2 (en) * 2013-11-06 2015-05-14 Raptor Pharmaceuticals Inc. Use of cysteamine and derivatives thereof to treat mitochondrial diseases

Similar Documents

Publication Publication Date Title
JP2023017050A5 (https=)
Bunya et al. Topical and oral voriconazole in the treatment of fungal keratitis
JP2020023574A5 (ja) 近視予防、治療又は抑制用点眼剤、及び、小胞体ストレス抑制用点眼剤
MX2020001403A (es) Nuevos derivados de quinolina.
MY208983A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
JP2019194191A5 (https=)
BR112018000592A2 (pt) composição de desbloqueio de nariz congestionado tendo atividade antiviral
JP2014533274A5 (https=)
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
RU2014123472A (ru) Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней
PH12021553202A1 (en) Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
AU2017261303A1 (en) Ophthalmic compositions
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
ZA202308388B (en) Nasal compositions comprising alcaftadine
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares
HRP20241509T1 (hr) Pripravak za oči koji sadrži bromfenak s povećanom bioraspoloživošću
JPWO2022249942A5 (https=)
WO2020128816A3 (en) Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
JP2018199643A5 (https=)
EP4338751A3 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
PH12022550003A1 (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
RU2007137115A (ru) Новые офтальмологические композиции и способы их применения
Rainer et al. Randomised fellow eye comparison of the effectiveness of dorzolamide and apraclonidine on intraocular pressure following phacoemulsification cataract surgery